Αxicabtagene ciloleucel
Brand names: YESCARTA
Therapeutic Indications
Αxicabtagene ciloleucel is indicated for:
Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
Irrespective of gender only Adults (18 - 65 years old)
Αxicabtagene ciloleucel is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy.
For this indication, the medical literature mentions below treatments (click for details):
Treatment 1: Intravenous - 68 ml once
Primary mediastinal large B-cell lymphoma (PMBCL)
Irrespective of gender only Adults (18 - 65 years old)
Αxicabtagene ciloleucel is indicated for the treatment of adult patients with primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy.
For this indication, the medical literature mentions below treatments (click for details):
Treatment 1: Intravenous - 68 ml once
Contraindications
Active ingredient Αxicabtagene ciloleucel is contraindicated in the following cases: